GLP-1 receptor agonist treatment reduces bone mineral density.
- Current status
- Preliminary signalEvidence stable · Bone
- Why
- In S-LiTE (adults with obesity, no diabetes), liraglutide alone was associated with lower hip and spine BMD than exercise alone after a year of weight maintenance, despite similar weight loss; exercise itself loads bone, and the abstract reports no liraglutide-versus-placebo BMD comparison. Exercise plus liraglutide left BMD unchanged versus placebo. Fracture outcomes are not available.
- What would change it
- Fracture-outcome data or BMD trials in adults over 60.
A weight-matched comparison isolating drug effect on bone. - Linked studies
- 1 · 1 consistent, but doesn't test the claim
- Last updated
- Oct 19, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Consistent, but doesn't test the claim (1)
- Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical TrialRandomized trial · 2024 · Study tier 2 · Different population · Harm direction · Partly industry funded
Secondary analysis of S-LiTE (n=195, mean age 42.84, no diabetes): after diet-induced weight loss, liraglutide alone lowered hip and spine BMD compared with exercise alone despite similar weight loss, while exercise plus liraglutide left BMD unchanged versus placebo. A liraglutide-alone versus placebo comparison is not reported in the abstract and fracture was not measured.
02History
How this assessment has changed
- Preliminary signalOct 19, 2026 · Evidence stable
Owner decision 2026-10-18 on IN-061 (claims audit): recommended options accepted (IN-061.28). Status unchanged; rationale corrected to match the audited links.
- Preliminary signalSep 13, 2026 · Evidence stable
initial curated status